SGCB and pulmonary arterial hypertension: There are three major classes of PAH-targeted drugs approved for PAH: endothelin receptor antagonists, prostacyclin analogs, and drugs targeting the NO-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway.